Petrus Trust Company, Lta Supernus Pharmaceuticals, Inc. Transaction History

Petrus Trust Company, Lta

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $250,107 - $323,860	8,362 New	8,362 $251,000
Q3 2020 Nov 16, 2020	SELL	$20.2 - $25.05 $239,895 - $297,493	-11,876 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $202,960 - $295,593	11,876 New	11,876 $282,000
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $158,346 - $207,461	-6,217 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$29.96 - $38.87 $111,720 - $144,946	-3,729 Reduced 37.49%	6,217 $206,000
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $84,284 - $107,998	2,572 Added 34.88%	9,946 $349,000
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $227,414 - $365,086	7,374 New	7,374 $245,000
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $212,048 - $280,827	-4,966 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $237,081 - $321,753	-5,376 Reduced 51.98%	4,966 $297,000
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $172,004 - $217,147	4,630 Added 81.06%	10,342 $474,000
Q4 2017 Feb 14, 2018	BUY	$36.4 - $42.6 $207,916 - $243,331	5,712	5,712 $228,000

303

60.7M

22.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.73B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Petrus Trust Company, Lta, based on Form 13F filings with the SEC.

Stay updated on Petrus Trust Company, Lta with notifications on news.